Gynecologic Oncology Update
by Dr. Neil Love
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇰🇷KR · Science#1321K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
500 to 5K🎙 Weekly cadence·34 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 10K🇰🇷100% - Active Followers
Loyal subscribers who consistently listen
300 to 3K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 22 epsHosts
Recent guests
Recent episodes
TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting
Aug 1, 2026
Unknown duration
For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress
Jul 23, 2026
Unknown duration
Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Jul 20, 2026
1h 29m 57s
Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Jul 15, 2026
2h 01m 19s
Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer
Jul 12, 2026
15m 08s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/1/26 | TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting | Featuring an interview with Dr Ramez Eskander, including the following topics:Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)Current and investigational targets of ADCs in gynecologic cancers (17:14)Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)CME information and select publications | — | ||||||
| 7/23/26 | For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress | Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)NCPD information and select publications | — | ||||||
| 7/20/26 | Endometrial CancerChemoimmunotherapy+4 | Dr Floor J BackesDr Brian M Slomovitz | — | — | Endometrial CancerChemoimmunotherapy+5 | — | 1h 29m 57s | ||
| 7/15/26 | Ovarian CancerPARP Inhibitors+3 | Dr Ramez N EskanderDr Ursula Matulonis+2 | — | — | Ovarian CancerPARP Inhibitors+5 | — | 2h 01m 19s | ||
| 7/12/26 | endometrial cancerneoadjuvant immunotherapy+3 | Dr Floor J BackesDr Matthew A Powell | SGO | — | endometrial cancerimmunotherapy+3 | — | 15m 08s | ||
| 7/10/26 | endometrial cancermolecular analyses+3 | Dr Floor J BackesDr Matthew A Powell | — | de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer | endometrial cancermolecular analyses+3 | — | 11m 23s | ||
| 7/7/26 | endometrial cancerimmunotherapy+3 | Dr Floor J Backes | Endometrial Cancer | — | endometrial cancerimmunotherapy+4 | — | 56m 05s | ||
| 7/6/26 | Antibody-Drug ConjugatesBreast Cancer+3 | Ms Courtney ArnMs Jamie Carroll+3 | Antibody-Drug ConjugatesHER2-Targeted ADCs+2 | — | Antibody-Drug ConjugatesHER2-Targeted ADCs+5 | — | 1h 28m 54s | ||
| 6/24/26 | Endometrial CancerFirst-Line Therapy+3 | Dr Dana M ChaseMs Sarah Karpen+2 | Endometrial Cancer | — | Endometrial CancerAdvanced EC+3 | — | 1h 28m 13s | ||
| 6/19/26 | Ovarian CancerPARP Inhibitors+4 | Dr Deborah K ArmstrongDr David M O’Malley | — | — | Ovarian CancerPARP Inhibitors+4 | — | 54m 28s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/17/26 | HER2-Positive Gynecologic CancersHER2-Targeted Therapy+3 | Dr Joyce F LiuDr Brian M Slomovitz | Trastuzumab DeruxtecanSociety of Gynecologic Oncology | — | HER2-PositiveGynecologic Cancers+5 | — | 1h 27m 59s | ||
| 6/3/26 | antibody-drug conjugatesgynecologic cancers+3 | Prof Ramez N EskanderDr Bradley J Monk+1 | UC San Diego Moores Cancer CenterFlorida Cancer Specialists & Research Institute+1 | — | antibody-drug conjugatesgynecologic oncology+3 | — | 1h 31m 15s | ||
| 5/21/26 | ovarian cancerclinical trials+3 | Prof Nicoletta ColomboDr Alexander Olawaiye+2 | European Institute of Oncology IRCCSUniversity of Pittsburgh School of Medicine+2 | — | ovarian cancerclinical trials+3 | — | 1h 28m 27s | ||
| 5/14/26 | immunotherapyendometrial cancer+3 | Dr Floor J BackesDr Matthew A Powell+1 | The James Cancer Hospital and Solove Research InstituteWashington University School of Medicine+1 | Columbus, OhioSt Louis, Missouri+1 | immunotherapyendometrial cancer+5 | — | 1h 29m 32s | ||
| 3/7/26 | ovarian cancertherapy selection+3 | Prof Nicoletta ColomboDr Kathleen N Moore | Gynecologic Oncology Update | — | ovarian cancertherapy sequencing+3 | — | 55m 39s | ||
| 2/16/26 | gynecologic cancersESMO Congress+3 | Dr Ritu Salani | David Geffen School of Medicine at UCLA | Los Angeles | gynecologic cancersESMO Congress 2025+3 | — | 57m 09s | ||
| 2/9/26 | ovarian cancerantibody-drug conjugates+3 | Dr Kathleen N Moore | Fred and Pamela Buffett Cancer Center | Omaha, Nebraska | ovarian cancerantibody-drug conjugates+4 | — | 54m 56s | ||
| 12/13/25 | ovarian cancertreatment landscape+3 | Dr Gottfried E Konecny | University of California, Los AngelesAmerican Oncology Network+1 | — | ovarian cancertreatment+3 | — | 48m 48s | ||
| 11/7/25 | endometrial cancertreatment strategies+3 | Dr Kathleen N MooreDr Matthew A Powell | OU Health Stephenson Cancer CenterWashington University School of Medicine | Oklahoma CitySt Louis | endometrial cancertreatment strategies+3 | — | 1h 00m 17s | ||
| 8/21/25 | ovarian cancerendometrial cancer+3 | Dr Shannon Westin | University of Texas MD Anderson Cancer CenterGynecologic Oncology Update | Houston | ovarian cancerendometrial cancer+3 | — | 52m 35s | ||
| 8/2/25 | gynecologic cancersovarian cancer+5 | Prof Susana BanerjeeDr Ursula Matulonis | The Institute of Cancer ResearchDana-Farber Cancer Institute | LondonBoston | gynecologic oncologycancer management+3 | — | 59m 34s | ||
| 7/21/25 | ovarian cancernursing considerations+3 | Ms Jennifer Filipi | Massachusetts General Hospital Cancer Center | Boston | ovarian cancernursing+5 | — | 53m 51s | ||
| 7/1/25 | ovarian cancerendometrial cancer+3 | Dr Joyce F LiuDavid M O’Malley+2 | — | — | ovarian cancerendometrial cancer+5 | — | 1h 59m 45s | ||
| 6/24/25 | ovarian cancerclinical treatment+3 | Dr David O’MalleyDr Shannon Westin | ONS Congress | — | ovarian cancertreatment landscape+3 | — | 1h 31m 27s | ||
| 6/6/25 | For Oncology Nurses: Endometrial Cancer — Proceedings from the 2025 Annual ONS Congress | Dr Ritu Salani and Dr Brian Slomovitz and nurse practitioners Ms Kathryn Lyle and Ms Jaclyn Shaver discuss datasets guiding treatment decision-making for patients with endometrial cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here. | — | ||||||
Showing 25 of 48
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Listen to Gynecologic Oncology
Gynecologic Oncology
SGO on the GO
The Society of Gynecologic Oncology
IJGC conversations
ijgcgroup
Gastrointestinal Cancer Update
Dr. Neil Love
Ready, Set, GYO!
Ready, Set, GYO: An educational gynecologic oncology podcast
ASCO Daily News
American Society of Clinical Oncology (ASCO)
Breast Cancer Update
Dr. Neil Love
Chart history for Gynecologic Oncology Update
Peaked at #132 in South Korea, currently #132 in South Korea.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| South Korea | — | #132 | #132 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.